Therapeutic area

Immune system disorders – page 96

1 641 clinical trials
555 recruiting
290 conditions
28 countries

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Click a country to filter the trials

Quick filters

1 641 clinical trials

Conjunctivitis allergic+3

Not recruiting

Study on the Effectiveness and Safety of a Grass and Olive Pollen Allergy Vaccine for Patients with Allergic Rhinitis or Asthma

Investigational

Study on the Effectiveness and Safety of a Grass and Olive Pollen Allergy Vaccine for Patients with Allergic Rhinitis or Asthma

Investigational

Spain

Participants:0–17 years · 18–64 years
Substances:Allergen Extract From Dactylis Glomerata Pollen, Glutaraldehyde-Modified
Sponsor:Inmunotek S.L.

Contact Research Centre

Acute myeloid leukaemia+10

Not recruiting

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

InvestigationalNo placebo

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

InvestigationalNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Conjunctivitis allergic+3

Not recruiting

Study on the Effectiveness and Safety of Clustoid MM09 for Patients with Allergic Rhinitis or Rhinoconjunctivitis, with or without Mild to Moderate Asthma

Investigational

Study on the Effectiveness and Safety of Clustoid MM09 for Patients with Allergic Rhinitis or Rhinoconjunctivitis, with or without Mild to Moderate Asthma

Investigational

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Dermatophagoides Farinae Allergoid, Glutaraldehyde-Modified
Sponsor:Inmunotek S.L.

Contact Research Centre

Juvenile idiopathic arthritis

Not recruiting

Study on the Safety and Effectiveness of Adalimumab and Etanercept in Children with Active Juvenile Idiopathic Arthritis

Registered drugNo placebo

Study on the Safety and Effectiveness of Adalimumab and Etanercept in Children with Active Juvenile Idiopathic Arthritis

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Adalimumab
Sponsor:Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

Contact Research Centre

Axial spondyloarthritis

Not recruiting

Study on the Effects of Risankizumab in Patients with Very Early Axial Spondyloarthritis

Registered drugNo placebo

Study on the Effects of Risankizumab in Patients with Very Early Axial Spondyloarthritis

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Risankizumab
Sponsor:St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr

Contact Research Centre

Eosinophilic oesophagitis

Not recruiting

Study on Budesonide Tablets for Treating Eosinophilic Esophagitis in Adults

Registered drug

Study on Budesonide Tablets for Treating Eosinophilic Esophagitis in Adults

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Budesonide
Sponsor:Dr. Falk Pharma GmbH

Contact Research Centre

Uveitis+1

Not recruiting

Study on Izokibep for Patients with Non-infectious Uveitis

Investigational

Study on Izokibep for Patients with Non-infectious Uveitis

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Izokibep
Sponsor:Acelyrin Inc.

Contact Research Centre

Graft versus host disease+1

Not recruiting

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational

Belgium

Participants:0–17 years · 18–64 years · 65+ years
Substances:Itolizumab
Sponsor:Equillium Inc.

Contact Research Centre

Cholangitis sclerosing

Not recruiting

Study on the Safety and Effectiveness of Elafibranor for Adults with Primary Sclerosing Cholangitis

Investigational

Study on the Safety and Effectiveness of Elafibranor for Adults with Primary Sclerosing Cholangitis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Elafibranor
Sponsor:Ipsen Bioscience Inc.

Contact Research Centre

Chronic spontaneous urticaria

Not recruiting

Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

Registered drug

Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Remibrutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug

Austria

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Amyloidosis

Not recruiting

Study of Belantamab Mafodotin for Patients with Relapsed or Refractory AL Amyloidosis

InvestigationalNo placebo

Study of Belantamab Mafodotin for Patients with Relapsed or Refractory AL Amyloidosis

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Belantamab Mafodotin
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trials Rituximab50 clinical trials Prednisone47 clinical trials Adalimumab40 clinical trials Emtricitabine39 clinical trials Tocilizumab38 clinical trials Tenofovir Alafenamide37 clinical trials Methotrexate36 clinical trials Prednisolone35 clinical trials

Immune system disorders – page 96

Conditions in this area

Clinical trials in Immune system disorders

1 641 clinical trials

Conjunctivitis allergic+3

Study on the Effectiveness and Safety of a Grass and Olive Pollen Allergy Vaccine for Patients with Allergic Rhinitis or Asthma

Acute myeloid leukaemia+10

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

Conjunctivitis allergic+3

Study on the Effectiveness and Safety of Clustoid MM09 for Patients with Allergic Rhinitis or Rhinoconjunctivitis, with or without Mild to Moderate Asthma

Juvenile idiopathic arthritis

Study on the Safety and Effectiveness of Adalimumab and Etanercept in Children with Active Juvenile Idiopathic Arthritis

Axial spondyloarthritis

Study on the Effects of Risankizumab in Patients with Very Early Axial Spondyloarthritis

Eosinophilic oesophagitis

Study on Budesonide Tablets for Treating Eosinophilic Esophagitis in Adults

Uveitis+1

Study on Izokibep for Patients with Non-infectious Uveitis

Graft versus host disease+1

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Cholangitis sclerosing

Study on the Safety and Effectiveness of Elafibranor for Adults with Primary Sclerosing Cholangitis

Chronic spontaneous urticaria

Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

Multiple sclerosis

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Amyloidosis

Study of Belantamab Mafodotin for Patients with Relapsed or Refractory AL Amyloidosis

Filter the trials

Substances studied in this area

Prefer not to search? Our Concierge searches the trials for you.